The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...

Novo Nordisk ( NVO 5.29%) stock ran up 3.5% through 10:05 a.m. ET Friday morning on some good news for it (and for Eli Lilly ...

The FDA announcement confirms that the U.S. supply of both prescription-only drugs now meets or exceeds the current and ...

The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk's popular weight-loss and ...

Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ...

The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...

Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug ...

The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022.

The FDA has announced that the shortage of Wegovy and Ozempic, medications used for weight loss and diabetes management, is ...

Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...